We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Abcam and Cell Marque Sign Global Strategic Marketing Agreement
News

Abcam and Cell Marque Sign Global Strategic Marketing Agreement

Abcam and Cell Marque Sign Global Strategic Marketing Agreement
News

Abcam and Cell Marque Sign Global Strategic Marketing Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Abcam and Cell Marque Sign Global Strategic Marketing Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Abcam plc and Cell Marque Corporation have announced that they have signed a global 10-year strategic marketing agreement for Abcam’s in vitro diagnostic (IVD) immunohistochemistry (IHC) RabMAb® primary antibody portfolio.

Under the agreement, Cell Marque will apply its extensive IVD expertise to incorporate Abcam’s IVD IHC RabMAb primary antibodies into its portfolio and use its established distribution channels to distribute them to the global market. The agreement will give customers faster, easier access to Abcam’s high-quality antibodies.

The antibodies use Abcam’s powerful RabMAb technology offering superior binding affinity and specificity, and have been specifically developed to provide high-quality results to pathology laboratories for immunohistochemical staining of formalin-fixed paraffin embedded (FFPE) tissue.

Alan Hirzel, Chief Marketing Officer, Abcam, commented: “We are excited about the growth opportunity that this agreement provides. Part of our strategy is to work with partners that offer complementary high-quality products and who share our vision of enabling researchers to discover more. The agreement with Cell Marque will enable Abcam to extend its reach within the in vitro diagnostics market, with a broader range of customers able to access our in-house developed RabMAb products.”

Nora Lacey, President and CEO of Cell Marque, commented: “The addition of Abcam’s IVD RabMAb products complements our current portfolio. The agreement with Abcam demonstrates Cell Marque’s ability to meet the quality and performance requirements of pathologists and will expand our offering of exceptional quality diagnostic tools.”

Advertisement